Intersect ENT Inc (NASDAQ:XENT) insider Lisa D. Earnhardt sold 20,000 shares of the stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $16.06, for a total transaction of $321,200.00. Following the completion of the transaction, the insider now owns 610,868 shares in the company, valued at approximately $9,810,540.08. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Intersect ENT Inc (NASDAQ:XENT) remained flat at $16.60 during midday trading on Tuesday. The company had a trading volume of 247,022 shares. The stock’s 50 day moving average is $15.80 and its 200 day moving average is $13.70. The firm’s market capitalization is $476.04 million. Intersect ENT Inc has a 12 month low of $7.65 and a 12 month high of $20.64.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings results on Tuesday, February 28th. The medical equipment provider reported ($0.17) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.03. Intersect ENT had a negative return on equity of 21.25% and a negative net margin of 35.69%. The business had revenue of $24.20 million for the quarter, compared to analyst estimates of $23.47 million. During the same quarter in the previous year, the firm earned ($0.20) earnings per share. The company’s revenue was up 28.7% on a year-over-year basis. Equities analysts forecast that Intersect ENT Inc will post ($0.79) EPS for the current year.

Insider Buying and Selling by Quarter for Intersect ENT (NASDAQ:XENT)

WARNING: “Intersect ENT Inc (XENT) Insider Sells $321,200.00 in Stock” was first published by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/04/18/intersect-ent-inc-xent-insider-sells-321200-00-in-stock.html.

Several large investors have recently modified their holdings of XENT. State Street Corp boosted its position in Intersect ENT by 12.8% in the fourth quarter. State Street Corp now owns 459,327 shares of the medical equipment provider’s stock valued at $5,550,000 after buying an additional 51,973 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in Intersect ENT by 129.4% in the third quarter. Adage Capital Partners GP L.L.C. now owns 400,000 shares of the medical equipment provider’s stock valued at $6,336,000 after buying an additional 225,649 shares during the period. Kopp Investment Advisors LLC boosted its position in Intersect ENT by 49.9% in the fourth quarter. Kopp Investment Advisors LLC now owns 357,795 shares of the medical equipment provider’s stock valued at $4,329,000 after buying an additional 119,097 shares during the period. Rock Springs Capital Management LP boosted its position in Intersect ENT by 1.5% in the third quarter. Rock Springs Capital Management LP now owns 345,000 shares of the medical equipment provider’s stock valued at $5,465,000 after buying an additional 5,000 shares during the period. Finally, Citadel Advisors LLC boosted its position in Intersect ENT by 386.8% in the third quarter. Citadel Advisors LLC now owns 331,952 shares of the medical equipment provider’s stock valued at $5,258,000 after buying an additional 263,768 shares during the period. Institutional investors and hedge funds own 77.81% of the company’s stock.

Several equities analysts have recently weighed in on XENT shares. Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of Intersect ENT in a research note on Wednesday, January 11th. Canaccord Genuity set a $16.00 price objective on shares of Intersect ENT and gave the stock a “buy” rating in a research note on Monday, January 23rd. Deutsche Bank AG upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating and increased their price objective for the stock from $15.00 to $19.00 in a research note on Monday, March 6th. Northland Securities reiterated a “buy” rating and issued a $17.00 price objective on shares of Intersect ENT in a research note on Monday, March 13th. Finally, Zacks Investment Research cut shares of Intersect ENT from a “hold” rating to a “strong sell” rating in a research note on Saturday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $18.00.

About Intersect ENT

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

5 Day Chart for NASDAQ:XENT

Receive News & Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related companies with MarketBeat.com's FREE daily email newsletter.